EPIZON
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 31 Jan 2025)
What this means for you
Registered since 05 Mar 2019. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 86984319
- Registration number
- 5692098
- Mark type
- Design + words
- Filed
- 17 Nov 2015
- Published for opposition
- 01 Nov 2016
- Registered
- 05 Mar 2019
- Attorney of record
- Alexander P. Montgomery
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations for the treatment of vascular disease, cardiovascular disease, heart disease, osteoporosis, bone disease, renal disease, kidney disease, autoimmune disease, atherosclerosis, excluding devices or drug systems for the delivery of pharmaceuticals for the treatment of allergic reactions, anaphylaxis, or asthma and pharmaceuticals for the treatment of allergic reaction, anaphylaxis or asthma
Owner
- Epizon Pharma, Inc., Woodbridge, CT, US
- Epizon Pharma, Inc., Woodbridge, CT, US
- Epizon Pharma, Inc., Woodbridge, CT, US
Prosecution history
- 31 Jan 2025 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 31 Jan 2025 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 31 Jan 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 13 Sept 2024 — TEAS SECTION 8 & 15 RECEIVED
- 05 Mar 2024 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 05 Mar 2019 — REGISTERED-PRINCIPAL REGISTER
- 31 Jan 2019 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 30 Jan 2019 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 04 Jan 2019 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 03 Jan 2019 — STATEMENT OF USE PROCESSING COMPLETE
- 19 Dec 2018 — USE AMENDMENT FILED
- 03 Jan 2019 — DIVISIONAL PROCESSING COMPLETE
- 19 Dec 2018 — DIVISIONAL REQUEST RECEIVED
- 19 Dec 2018 — TEAS REQUEST TO DIVIDE RECEIVED
- 19 Dec 2018 — TEAS STATEMENT OF USE RECEIVED